Guardant Health, Inc. (GH), a precision oncology company, Thursday said its stock has been halted temporarily from trading on Nasdaq. The U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee is expected to meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health's blood test to screen for colorectal cancer.

精准肿瘤公司Guardant Health，Inc.（GH）周四表示，其股票已在纳斯达克暂时停牌。美国食品和药物管理局（FDA）医疗器械咨询委员会预计今天开会，审查ShieldTM上市前批准（PMA）申请，ShieldTM是Guardant Health筛查结直肠癌的血液检测。